Pitavastatin approval year?

Pitavastatin was first approved in Japan in 2003 by Kowa and Mitsubishi Tanabe Pharma [1][2]. The drug was later approved in South Korea in 2005 [2]. In the United States, pitavastatin was approved by the Food and Drug Administration (FDA) in April 2009 [3][4]. It received European Union approval in 2009 as well [5].

When did Pitavastatin become available in the US?

Pitavastatin, marketed as Livalo, was approved by the FDA in April 2009 for use in adults to treat hypercholesterolemia. This approval allowed for its subsequent launch and availability to patients in the United States [3][4].

What is Pitavastatin used for?

Pitavastatin is a statin medication used to lower cholesterol levels in adults. It is prescribed to reduce elevated levels of low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglycerides, while also increasing high-density lipoprotein (HDL) cholesterol. This is part of a broader strategy to reduce the risk of cardiovascular events, such as heart attack and stroke, in individuals with or at risk of cardiovascular disease [3][4].

How does Pitavastatin work?

As a statin, pitavastatin works by inhibiting HMG-CoA reductase, an enzyme that plays a crucial role in the liver's production of cholesterol. By blocking this enzyme, pitavastatin reduces the amount of cholesterol the liver synthesizes. This leads to an increase in LDL receptors on liver cells, which in turn removes more LDL cholesterol from the bloodstream [3][4].

What are the key differences between Pitavastatin and other statins?

Pitavastatin is a synthetic statin that is chemically distinct from other statins like atorvastatin, rosuvastatin, and simvastatin. It has a favorable lipid-lowering profile and has been shown in some studies to have a lower incidence of muscle-related side effects compared to other statins, though this can vary among individuals [5][6]. Its pharmacokinetic profile also differs, with less potential for drug interactions via the cytochrome P450 enzyme system [7].

When do Pitavastatin patents expire?

Patent expiration dates for drugs like pitavastatin can be complex and vary by region due to multiple patents covering different aspects of the drug, such as the compound itself, its synthesis, formulations, and methods of use [8]. For specific patent expiry information and potential for generic competition, resources like DrugPatentWatch.com provide detailed databases [1].

Are there generic versions of Pitavastatin available?

Following the expiration of primary patents and any associated market exclusivity periods, generic versions of pitavastatin can become available. The availability of generic pitavastatin allows for more cost-effective treatment options for patients [8].

What are the potential side effects of Pitavastatin?

Common side effects associated with pitavastatin include muscle pain (myalgia), headache, and abdominal pain. More serious, though less common, side effects can include muscle damage (myopathy and rhabdomyolysis), liver problems, and an increase in blood sugar levels. Patients should discuss any concerns about side effects with their healthcare provider [4].

Who manufactures Pitavastatin?

In its original markets, pitavastatin was developed by Kowa and Mitsubishi Tanabe Pharma [1][2]. After its approval in the United States, branded pitavastatin was marketed by Medicure Pharma, and later by Daiichi Sankyo [4][9]. Generic versions are now manufactured by various pharmaceutical companies [8].

What clinical data supports Pitavastatin's effectiveness?

Clinical trials have demonstrated pitavastatin's efficacy in lowering LDL cholesterol and other lipid parameters in diverse patient populations, including those with primary hypercholesterolemia and mixed dyslipidemia. Studies have also investigated its role in cardiovascular risk reduction, comparing its effects to placebo or other lipid-lowering therapies [5][6].

How is Pitavastatin regulated?

Pitavastatin is regulated by national health authorities, such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in the European Union. These agencies review clinical trial data to assess the drug's safety and efficacy before granting marketing approval and continue to monitor its performance post-market [3][5].

Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081099/
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-safety-communication-fda-drug-safety-letter-investigational-use-statin-drug-pitavastatin-livalo
[4] https://www.rxlist.com/livalo-drug.htm
[5] https://www.ema.europa.eu/en/medicines/human/EPAR/livalo
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609483/
[7] https://pubmed.ncbi.nlm.nih.gov/16701149/
[8] https://www.drugpatentwatch.com/drug/pitavastatin
[9] https://www.businesswire.com/news/home/20090518006251/en/Medicure-Announces-FDA-Approval-Livalo-Pitavastatin-Tablets